	US 11,939,606 B2
	CRISPR-associated (Cas) protein
Matthew Merrill Carter, San Diego, CA (US); and Paul Daniel Donohoue, San Diego, CA (US)
Assigned to Locanabio, Inc., San Diego, CA (US)
Filed by Locanabio, Inc., San Diego, CA (US)
Filed on Feb. 23, 2022, as Appl. No. 17/678,369.
Application 17/678,369 is a division of application No. 17/097,880, filed on Nov. 13, 2020, granted, now 11,293,011.
Application 17/097,880 is a continuation of application No. 15/937,840, filed on Mar. 27, 2018, granted, now 10,876,101, issued on Dec. 29, 2020.
Claims priority of provisional application 62/629,641, filed on Feb. 12, 2018.
Claims priority of provisional application 62/477,494, filed on Mar. 28, 2017.
Prior Publication US 2022/0177864 A1, Jun. 9, 2022
Int. Cl. C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01)

CPC C12N 9/22 (2013.01) [C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/1136 (2013.01); C12N 15/85 (2013.01); C12N 2310/20 (2017.05); C12N 2800/22 (2013.01)]

13 Claims

1. A Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex, wherein the nucleoprotein complex comprises a Cas protein having at least 95 percent sequence identity to the amino acid sequence of SEQ ID NO: 40; and

a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.